T1	Participants 77 140	diabetic patients undergoing percutaneous coronary intervention
T2	Participants 0 231;233 457	Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. BACKGROUND The platelet glycoprotein IIb/IIIa receptor inhibitor abciximab, a monoclonal antibody, has been shown to improve early and late outcomes among diabetic patients undergoing percutaneous coronary intervention (PCI)
T3	Participants 552 617	8 countries, 4809 patients undergoing PCI with stent implantation
T4	Participants 1625 1657	diabetic patients undergoing PCI
T5	Participants 1940 1957	diabetic patients
